{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:46:44Z","timestamp":1788864404006,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a heterogeneous, immune-mediated disease that significantly impacts quality of life, functional capacity, and healthcare systems. Over the past two decades, treatment options have expanded from conventional therapies to biologic and targeted synthetic DMARDs, enabling more effective disease control. However, many patients still fail to achieve remission or low disease activity (LDA), reflecting challenges in selecting the right treatment at the right time for the right patient. This perspective introduces a conceptual framework for PsA management using the metaphor of a journey, emphasizing three key dimensions: patient heterogeneity (\u201cvehicle\u201d), therapeutic options (\u201cfuel\u201d), and the timing of the intervention (\u201croad\u201d). Aligning these factors can optimize care, reduce disease burden, and improve long-term outcomes.<\/jats:p>","DOI":"10.3390\/jcm14217713","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:28:43Z","timestamp":1761888523000},"page":"7713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Navigating the Journey in Psoriatic Arthritis: Matching the Right Patient, the Right Drug, and the Right Time"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"first","affiliation":[{"name":"Academic Rheumatology Unit, Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Via Giovanni Paolo II, C\/da Tappino, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-6891","authenticated-orcid":false,"given":"Mauro","family":"Fatica","sequence":"additional","affiliation":[{"name":"Academic Rheumatology Unit, Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Via Giovanni Paolo II, C\/da Tappino, 86100 Campobasso, Italy"},{"name":"Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Italiano","sequence":"additional","affiliation":[{"name":"Academic Rheumatology Unit, Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Via Giovanni Paolo II, C\/da Tappino, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-5205","authenticated-orcid":false,"given":"Fabio Massimo","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Academic Rheumatology Unit, Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Via Giovanni Paolo II, C\/da Tappino, 86100 Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: State of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/14712598.2024.2384090","article-title":"The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis","volume":"24","author":"Caso","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000528945","article-title":"Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"key":"ref_5","first-page":"997","article-title":"Health care utilization and costs associated with functional status in patients with psoriatic arthritis","volume":"28","author":"Ogdie","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ii74","DOI":"10.1136\/ard.2004.030783","article-title":"Psoriatic arthritis therapy: NSAIDs and traditional DMARDs","volume":"64 Suppl 2","author":"Nash","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","first-page":"S104","article-title":"A short history of biological therapy for psoriatic arthritis","volume":"33","author":"Mease","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/14712598.2022.2152321","article-title":"What\u2019s new and what\u2019s next for biological and targeted synthetic treatments in psoriatic arthritis?","volume":"22","author":"Sunzini","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11926-015-0517-0","article-title":"Treat to target in psoriatic arthritis-evidence, target, research agenda","volume":"17","author":"Coates","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease Activity in Psoriatic Arthritis (DAPSA): Defining Remission and Treatment Success Using the OMERACT Filter","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/annrheumdis-2016-211010","article-title":"Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS)","volume":"77","author":"Helliwell","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining Minimal Disease Activity in Psoriatic Arthritis: A Proposed Objective Target for Treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40744-023-00588-4","article-title":"Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis","volume":"10","author":"Scriffignano","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin. Arthritis. Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e001728","DOI":"10.1136\/rmdopen-2021-001728","article-title":"Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: A cluster analysis in the worldwide ASAS-PerSpA study","volume":"7","author":"Chevret","year":"2021","journal-title":"RMD Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105692","DOI":"10.1016\/j.jbspin.2024.105692","article-title":"Molecular portrait of chronic joint diseases: Defining endotypes toward personalized medicine","volume":"91","author":"Ghirardi","year":"2024","journal-title":"Joint Bone Spine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic heterogeneity in psoriatic arthritis: Towards tissue pathology-based therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Miyagawa, I., Nakayamada, S., Ueno, M., Miyazaki, Y., Ohkubo, N., Inoue, Y., Kubo, S., and Tanaka, Y. (2022). Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front. Med., 9.","DOI":"10.3389\/fmed.2022.934937"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: Towards patient-centric precision medicine","volume":"16","author":"Pitzalis","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/1744666X.2021.1825941","article-title":"Multimorbidity and comorbidity in psoriatic arthritis\u2014A perspective","volume":"16","author":"Lubrano","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_23","first-page":"CD013614","article-title":"Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis","volume":"13","author":"Cagnotto","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","article-title":"Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis","volume":"2","author":"Savage","year":"2015","journal-title":"Rheumatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/msc.1694","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20","author":"Fragoulis","year":"2022","journal-title":"Musculoskeletal. Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis","volume":"59","author":"Simopoulou","year":"2023","journal-title":"Drugs Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/1744666X.2021.1925541","article-title":"JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: A critical review of clinical trials","volume":"17","author":"Keeling","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_28","first-page":"S98","article-title":"Apremilast in psoriatic arthritis","volume":"33","author":"Schett","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ard.2025.05.117","article-title":"OP0095 Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis","volume":"84","author":"Mease","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ard.2025.05.118","article-title":"OP0096 Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: Results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial","volume":"84","author":"McInnes","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ard.2025.02.019","article-title":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: A randomised, double-blind, placebo-controlled, phase 2 study","volume":"84","author":"Taylor","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e003423","DOI":"10.1136\/rmdopen-2023-003423","article-title":"Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: A network meta-analysis","volume":"10","author":"Mease","year":"2024","journal-title":"RMD Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40264-024-01461-1","article-title":"A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a \u201cSafety Checklist\u201d","volume":"47","author":"Skaarup","year":"2024","journal-title":"Drug Saf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1759720X211014010","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: A systematic review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3899\/jrheum.201199","article-title":"Diagnostic Delay in Psoriatic Arthritis: A Population-based Study","volume":"48","author":"Karmacharya","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e004062","DOI":"10.1136\/rmdopen-2023-004062","article-title":"Window of opportunity in psoriatic arthritis: The earlier the better?","volume":"10","author":"Luime","year":"2024","journal-title":"RMD Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/ard-2024-225833","article-title":"Treatment of early oligoarticular psoriatic arthritis with apremilast: Primary outcomes at week 16 from the FOREMOST randomised controlled trial","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41584-021-00578-2","article-title":"Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: Results from a Delphi consensus study","volume":"17","author":"Haberman","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e004314","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: Exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/PTT.S323300","article-title":"Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis","volume":"12","author":"Gisondi","year":"2022","journal-title":"Psoriasis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.det.2024.02.014","article-title":"Prevention of Psoriatic Arthritis: The Need for Prospective Studies","volume":"42","author":"Wu","year":"2024","journal-title":"Dermatol. Clin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/rheumatology\/keae399","article-title":"Subclinical psoriatic arthritis and disease interception-where are we in 2024?","volume":"64","author":"McGonagle","year":"2025","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(24)00268-6","article-title":"Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease","volume":"7","author":"Ciccia","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"LoGiudice","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40257-023-00801-8","article-title":"Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review","volume":"24","author":"Aronovich","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-023-01072-1","article-title":"Biologics in Prevention of Psoriasis to Psoriatic Arthritis Transition: The Need of Prospective Analyses and Stratification According to Time-Related Risk Factors","volume":"14","author":"Errichetti","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"de Camargo, M.C., Barros, B.C.A., Fulone, I., Silva, M.T., Silveira, M.S.D.N., de Camargo, I.A., Barberato-Filho, S., Del Fiol, F.S., and Lopes, L.C. (2019). Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00965"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"24922","DOI":"10.1038\/s41598-024-75190-x","article-title":"Cycling versus swapping strategies with TNF-\u03b1 inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice","volume":"14","author":"Lumetti","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e25300","DOI":"10.1097\/MD.0000000000025300","article-title":"Cycling or swap biologics and small molecules in psoriatic arthritis: Observations from a real-life single center cohort","volume":"100","author":"Ariani","year":"2021","journal-title":"Medicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e005566","DOI":"10.1136\/rmdopen-2025-005566","article-title":"Cycle versus swap strategy after TNFi discontinuation in psoriatic arthritis and axial spondyloarthritis: A quasi-experimental study","volume":"11","author":"Vriezekolk","year":"2025","journal-title":"RMD Open"},{"key":"ref_55","first-page":"200","article-title":"Cycling versus swapping strategies in psoriatic arthritis: Results from the rheumatic diseases Portuguese register","volume":"2","author":"Ferreira","year":"2023","journal-title":"ARP Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3899\/jrheum.190054","article-title":"Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?","volume":"46","author":"Lubrano","year":"2019","journal-title":"J. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:48:37Z","timestamp":1761889717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":56,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217713"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217713","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}